Status:

COMPLETED

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

Lead Sponsor:

Ascendis Pharma A/S

Conditions:

Achondroplasia

Eligibility:

All Genders

2-10 years

Phase:

PHASE2

Brief Summary

The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10 years old, inclusive,...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of ACH with genetic confirmation
  • Age between 2 to 10 years old (inclusive) at Screening Visit
  • Prepubertal (Stage 1 breasts for girls or testicular volume \< 4ml for boys) at Screening Visit
  • Able to stand without assistance
  • Caregiver willing and able to administer subcutaneous injections of study drug

Exclusion

  • Clinically significant findings at Screening that:
  • are expected to require surgical intervention during participation in the trial or
  • are musculoskeletal in nature, such as Salter-Harris fractures and severe hip pain or
  • otherwise are considered by investigator or Medical Monitor/Medical Expert to make a participant unfit to receive study drug or undergo trial related procedures
  • Have received treatment (\>3 months) of human growth hormone (hGH) or other medications known to affect stature or body proportionality at any time
  • Have received any dose of medications intended to affect stature or body proportionality within the previous 6 months of Screening Visit
  • Have received any study drug or device intended to affect stature or body proportionality at any time
  • History or presence of injury or disease of the growth plate(s), other than Achondroplasia, that affects growth potential of long bones

Key Trial Info

Start Date :

June 24 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2024

Estimated Enrollment :

57 Patients enrolled

Trial Details

Trial ID

NCT04085523

Start Date

June 24 2020

End Date

October 1 2024

Last Update

May 22 2025

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Ascendis Pharma Investigational Site

Little Rock, Arkansas, United States, 72211

2

Ascendis Pharma Investigational Site

Aurora, Colorado, United States, 80045

3

Ascendis Pharma Investigational Site

Saint Paul, Minnesota, United States, 55102

4

Ascendis Pharma Investigational Site

Columbia, Missouri, United States, 65212